ArticleJournal of translational medicine2026
ATAD3A promotes bladder cancer progression by regulating glycolysis through MYC stabilization.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundBladder cancer (BCa) remains a major global health challenge with high recurrence and progression rates. Although metabolic reprogramming is recognized as a hallmark of cancer, the molecular mechanisms driving glycolysis in BCa are incompletely understood. ATAD3A, a mitochondrial membrane protein implicated in various malignancies, has not been characterized in BCa. This study aimed to investigate the role of ATAD3A in BCa progression and elucidate the molecular mechanisms linking ATAD3A to tumor metabolism.
methodsTCGA-BLCA data were analyzed to assess ATAD3A expression and its association with clinical outcomes. Functional assays, including CCK-8, colony formation, EdU incorporation, Transwell migration/invasion, wound healing, and Seahorse metabolic flux analysis (ECAR and OCR), were conducted in BCa cell lines with ATAD3A knockdown or overexpression. Subcutaneous xenograft models were used to evaluate tumor growth in vivo. Quantitative proteomics identified downstream pathways. Mechanistic studies included cycloheximide chase assays, proteasome inhibition, ubiquitination assays, immunofluorescence, and co-immunoprecipitation to explore the regulation of MYC stability by ATAD3A and USP10.
resultsATAD3A was significantly upregulated in BCa and associated with advanced stage and poor prognosis. ATAD3A knockdown suppressed proliferation, migration, invasion, and tumor growth, whereas overexpression enhanced these malignant phenotypes. Proteomics revealed enrichment of glycolysis pathways upon ATAD3A overexpression, and functional assays confirmed ATAD3A-dependent increases in lactate production and glucose uptake. Glycolysis inhibition with 2-DG abolished ATAD3A-driven phenotypes. Mechanistically, ATAD3A stabilized MYC protein without affecting its mRNA levels, prolonging MYC half-life by suppressing ubiquitin-proteasome-mediated degradation. USP10 was identified as a key mediator, directly interacting with MYC and reducing its poly-ubiquitination. Rescue experiments confirmed that USP10 or MYC restoration overcame the suppressive effects of ATAD3A knockdown both in vitro and in vivo.
conclusionOur findings demonstrate that ATAD3A drives BCa progression by promoting USP10-mediated stabilization of MYC and enhancing glycolytic reprogramming. The ATAD3A-USP10-MYC axis represents a potential therapeutic target for BCa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.